Hematology

Clinical pharmacy services in hematology can have a significant impact, and the Pharmacy Times® Hematology resource center provides clinical news and articles about the topic. Here, visitors will find information about upcoming hematology conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
The study is one of the largest to ever use nutritional biomarkers to investigate bioactive compounds in lowering blood pressure.
 
[[thumbnail_alt_text]]
The FDA granted fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the treatment of chronic lymphocytic leukemia.
[[thumbnail_alt_text]]
The FDA action was based on results from the Phase 3 CheckMate -9ER trial evaluating nivolumab in combination with cabozantinib compared with sunitinib among patients with previously untreated advanced RCC.
[[thumbnail_alt_text]]
Venetoclax was granted accelerated approval in November 2018, as well as priority review, breakthrough designation, and orphan drug designation.
 
[[thumbnail_alt_text]]
A recent study found that where you live affects the risk of chronic conditions, such as high blood pressure and depression. 
 
[[thumbnail_alt_text]]
The FDA approved an expanded label for for pembrolizumab for adult patients with relapsed or refractory classical Hodgkin lymphoma.
[[thumbnail_alt_text]]
Hospitalized patients with COVID-19 treated with enoxaparin were found to have lower rates of thrombosis, kidney injury, and mortality than patients treated with unfractionated heparin.
[[thumbnail_alt_text]]
Copanlisib (Aliqopa) in combination with rituximab (Rituxan) prolonged progression-free survival in patients with non-Hodgkin lymphoma who relapsed following 1 or more previous lines of rituximab-based therapy.
[[thumbnail_alt_text]]
Pacritinib is a JAK2/FLT3 inhibitor for the treatment of patients with myelofibrosis and severe thrombocytopenia defined as platelet counts of less than 50,000 μL.
[[thumbnail_alt_text]]
In the absence of a direct head-to-head clinical trial, study may help inform treatment selections for stem cell transplant-ineligible patients.
 
[[thumbnail_alt_text]]
KG is a female patient aged 44 years who came to the pharmacy with a prescription that the pharmacist recognized is the treatment regimen for a new blood clot.